Researchers who have harnessed the body’s immune system to fight cancer have found a way to make the approach work even better, using an ordinary tetanus vaccine.
They used their double-vaccine approach to greatly lengthen the lives of patients with one of the deadliest types of cancer — the brain tumor glioblastoma.
“Patients with glioblastoma usually survive for little more than one year. However, in patients who received the immunotherapy, half lived nearly five years or longer from their diagnosis,” said Dr. John Sampson of Duke University Medical Center, who oversaw the study.
The team has been using what is…
Read the rest of the story from our partners at NBC News
Get The Brief. Sign up to receive the top stories you need to know right now.
More Must-Reads From TIME
- Essay: The Tyre Nichols Videos Demand Solemnity, Not Sensationalism
- For People With Disabilities, Losing Abortion Access Can Be a Matter of Life or Death
- Inside the Stealth Efforts to Smuggle Starlink Internet Into Iran
- Natasha Lyonne on Poker Face and Creating Characters Who Subvert Leading-Lady Tropes
- How to Help the Victims and Community After the Monterey Park Shooting
- Why Grocery Staples Are So Expensive Right Now
- Quantum Computers Could Solve Countless Problems—and Create a Lot of New Ones
- Where to Watch All of the 2023 Oscar Nominees
- How to Be Mindful if You Hate Meditating
